Condition

HNSCC clinical trials and research

• 40Clinical trials
• 53NIH research projects
• 2New in 30 days
• 20Countries

Newest HNSCC clinical trials

All recruiting trials (40)

• TMV vaccine alone or with toripalimab for recurrent head and neck cancer

  This study tests a personalized TMV vaccine, alone and with toripalimab, in adults whose head and neck cancer has returned and is planning salvage surgery.

  Recruiting Phase 1 Metaclipse Therapeutics Corporation · Houston, Texas · NCT07898124

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• TS-104: a first-in-human, dose-escalation study for advanced solid tumors

  This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.

  Recruiting at 3 sites Phase 1 TwoStep Therapeutics, Inc. · Maumee, Ohio and 2 other locations · NCT07814248

• Intratumoral fluorescent nivolumab before surgery in head and neck cancer

  This study tests injecting fluorescently labeled nivolumab directly into head and neck tumors to see if it is safe and whether it reaches nearby lymph nodes before surgical removal.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07741565

• SKB571 in recurrent or metastatic head and neck cancer in adults

  This study tests SKB571, alone or with Pembrolizumab and platinum chemotherapy, to see if it helps adults with recurrent or metastatic head and neck cancer.

  Recruiting at 2 sites Phase 2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Chengdu and 1 other locations · NCT07668154

• Proton versus photon treatment for squamous cell cancers of the head and neck

  This trial will test whether proton radiation or standard photon radiation leads to less long-term dry mouth, swallowing problems, pain, and speech issues in people aged 40 and older with squamous cell cancers of the oral cavity, oropharynx, hypopharynx, or larynx treated with curative radiotherapy.

  Recruiting Phase 3 Oslo University Hospital · Bergen and 3 other locations · NCT07580300

• EPI-326 for EGFR-mutant non-small cell lung cancer and head and neck squamous cell carcinoma

  This phase 1 trial will try EPI-326, a new drug, in people with EGFR-mutant non‑small cell lung cancer or advanced head and neck squamous cell carcinoma to find safe doses, study how the body handles it, and look for early signs it shrinks tumors.

  Recruiting at 8 sites Phase 1 EpiBiologics · Los Angeles, California and 7 other locations · NCT07462377

• Nivolumab-IRDyE800CW imaging agent used before surgery in head and neck cancer

  This early-stage trial tests whether nivolumab labeled with IRDye800CW can safely be given before surgery to see if it helps image head and neck squamous cell carcinoma.

  Recruiting Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07460765

• NRM-823 for advanced or metastatic refractory solid tumors

  This trial tests whether NRM-823 is safe and can help people with advanced or metastatic head and neck, esophageal, gastric, or related cancers.

  Recruiting at 18 sites Phase 1 Normunity AccelCo, Inc. · Denver, Colorado and 17 other locations · NCT07182149

• HCB101 plus pembrolizumab for platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma

  This trial tests whether adding HCB101 to pembrolizumab is safe and helps people with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.

  Recruiting at 3 sites Phase 1/2 Taipei Veterans General Hospital, Taiwan · Taoyuan, Guishan District and 2 other locations · NCT07136545

• Testing GV20-0251 for advanced or treatment‑resistant solid tumors

  This study will test whether GV20-0251 is safe and tolerable when given every three weeks to adults with advanced or treatment‑resistant solid tumors such as liver, lung, pancreatic cancer, and melanoma.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07106827

• ALX2004 for advanced or metastatic EGFR-expressing solid tumors

  This trial will test ALX2004, an antibody-drug conjugate that targets EGFR, in people with advanced or metastatic non-small cell lung, head and neck, esophageal, or colorectal cancer to see if it is safe and shows tumor activity.

  Recruiting at 11 sites Phase 1 ALX Oncology Inc. · La Jolla, California and 11 other locations · NCT07085091

• TI-0093 injection for recurrent or metastatic HPV-16 positive solid tumors

  This study will try TI-0093, a therapeutic tumor vaccine given by injection, in adults with recurrent or metastatic HPV‑16 positive cancers to see if it is safe and prompts an immune response and possible tumor benefit.

  Recruiting Phase 1 Therorna · Shanghai · NCT07081984

• Finotonlimab plus Stapokibart for recurrent or metastatic head and neck cancer

  This trial will see if combining Finotonlimab with Stapokibart helps adults with recurrent or metastatic head and neck squamous cell carcinoma who progressed after PD‑1 therapy.

  Recruiting Phase 1 Beijing Tongren Hospital · Beijing, Beijing Municipality · NCT07040072

• DCSZ11 combined with standard therapy for advanced or metastatic solid tumors

  This will test whether adding DCSZ11 to standard treatments helps adults with advanced or metastatic solid tumors.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07035249

• High-resolution PET-CT to visualize surgical tumor margins

  This will test whether a low-dose, high-resolution PET-CT scan of removed tumor tissue can help surgeons spot at-risk margins during surgery for adults with solid cancers such as head and neck squamous cell carcinoma.

  Recruiting Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT06915454

• Using a fluorescently labeled drug to improve surgery for head and neck cancer

  This study is testing a special version of a cancer drug to see if it can help doctors see tumors better during surgery for patients with head and neck cancer.

  Recruiting Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT06819228

• Investigating OKN4395 and Pembrolizumab for Solid Tumors

  This study is testing a new drug called OKN4395, alone and with another drug called pembrolizumab, to see if it can help people with solid tumors who have run out of other treatment options.

  Recruiting at 10 sites Phase 1 Epkin · Beverly Hills, California and 9 other locations · NCT06789172

• Using a 3D culture model to study circulating tumor cells in head and neck cancer

  This study is trying to see how circulating tumor cells from patients with head and neck cancer behave in a lab setting to better understand how the cancer spreads and comes back.

  Recruiting Chang Gung Memorial Hospital · Taoyuan · NCT06755762

• Injecting a viral particle to treat head and neck cancer

  This study is testing a new virus injection to see if it can help treat head and neck cancer in different groups of patients.

  Recruiting Phase 1 VLP Therapeutics · Stanford, California · NCT06736379

• Evaluating the effects of AHCC in HPV-positive head and neck cancer patients

  This study is testing whether AHCC capsules are safe and well-tolerated for adults with HPV-positive head and neck cancer who are undergoing surgery.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06693323

• Evaluating a new CAR T-cell therapy for solid tumors expressing EGFR

  This study is testing a new CAR T-cell therapy to see if it can safely help adults with certain solid tumors, like colorectal and lung cancer, that have specific markers.

  Recruiting at 10 sites Phase 1/2 A2 Biotherapeutics Inc. · Gilbert, Arizona and 9 other locations · NCT06682793

• Testing TUB-030 for advanced solid tumors

  This study is testing a new drug called TUB-030 to see if it can safely help adults with advanced solid tumors, especially those with head and neck cancer or non-small cell lung cancer.

  Recruiting at 19 sites Phase 1/2 Gilead Sciences · New Haven, Connecticut and 19 other locations · NCT06657222

• Investigating ADCE-T02 for advanced solid tumors

  This study is testing a new drug called ADCE-T02 to see if it can safely help people with advanced solid tumors that can't be surgically removed.

  Recruiting at 14 sites Phase 1 Adcendo ApS · Rogers, Arkansas and 13 other locations · NCT06597721

• Using 177Lu-anti-PD-L1 for treating metastatic solid tumors

  This study is testing a new treatment called 177Lu-RAD204 to see if it can safely help people with advanced solid tumors like lung cancer and melanoma.

  Recruiting at 4 sites Early Phase 1 Radiopharm Theranostics, Ltd · Gosford, New South Wales and 5 other locations · NCT06305962

• Treatment with SPX-303 for patients with solid tumors

  This study is testing a new treatment called SPX-303 for patients with solid tumors that haven't improved with previous therapies to see if it can help them feel better.

  Recruiting at 4 sites Phase 1 SparX Biotech(Jiangsu) Co., Ltd. · Phoenix, Arizona and 3 other locations · NCT06259552

• Using GT201 with PD-1 inhibitors for advanced head and neck tumors

  This study is testing if a new treatment called GT201, when used with a PD-1 inhibitor, can be safe and effective for people with advanced head and neck tumors.

  Recruiting Grit Biotechnology · Shanghai, Shanghai Municipality · NCT06190275

• Evaluating YL202 for Patients with Advanced Solid Tumors

  This study is testing a new treatment called YL202 to see if it can help people with advanced solid tumors like lung, breast, and head and neck cancers feel better.

  Recruiting at 48 sites Phase 2 MediLink Therapeutics (Suzhou) Co., Ltd. · Hefei, Anhui and 81 other locations · NCT06107686

• Combining a DNA vaccine with pembrolizumab for HPV-positive head and neck cancer

  This study is testing a new DNA vaccine combined with pembrolizumab to see if it helps people with advanced HPV-positive head and neck cancer.

  Recruiting at 12 sites Phase 1/2 Nykode Therapeutics ASA · Montpellier and 11 other locations · NCT06016920

• Comparing PD-1 inhibitor therapy to radiotherapy for advanced head and neck cancer after immunochemotherapy

  This study is testing if a new type of cancer treatment called PD-1 inhibitor therapy can be a better option than regular radiotherapy for patients with advanced head and neck cancer who have responded well to earlier treatment.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT05980715

• Comparing two and four courses of pembrolizumab with chemotherapy for head and neck cancer

  This study is testing whether getting two or four rounds of a new cancer drug along with chemotherapy helps people with head and neck cancer do better before surgery.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT05980702

• Evaluating CJRB-101 with Pembrolizumab for Advanced Cancer

  This study is testing a new treatment combining CJRB-101 with pembrolizumab to see if it helps people with advanced cancers like lung cancer and melanoma feel better and respond better to their treatment.

  Recruiting at 4 sites Phase 1/2 CJ Bioscience, Inc. · Irvine, California and 3 other locations · NCT05877430

• MQ710 with or without pembrolizumab for advanced skin and other solid tumors

  This will test different doses of MQ710, alone or together with pembrolizumab, in adults with advanced or recurrent solid tumors (including skin cancers) to find a safe dose with mild side effects.

  Recruiting at 5 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05859074

• Care patterns for elderly patients with head and neck cancer receiving radiotherapy

  This study is looking at how well elderly patients with advanced head and neck cancer do with radiation treatment and chemotherapy to see if it helps them live longer and stay healthier.

  Recruiting University Hospital Freiburg · Baltimore, Maryland and 17 other locations · NCT05337631

• Using AI to personalize treatment for head and neck cancer patients

  This study is testing whether using artificial intelligence to analyze PET scans and patient data can help doctors create more personalized treatment plans for people with head and neck cancer.

  Recruiting Charite University, Berlin, Germany · Berlin · NCT05192655

• Combining immune checkpoint inhibitors with radiotherapy for cancer treatment

  This study is testing if combining immune checkpoint inhibitors with radiotherapy can improve treatment for patients with certain types of cancer, like head and neck and lung cancer.

  Recruiting University of Erlangen-Nürnberg Medical School · Erlangen, Bavaria · NCT04892849

• Combining chemotherapy and immunotherapy for head and neck cancer treatment

  This study is testing if combining chemotherapy with immunotherapy drugs can help people with head and neck cancer before surgery and possibly reduce the need for radiation therapy afterward.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT04722523

• Treatment of advanced solid tumors with T3011 and pembrolizumab

  This study is testing a new treatment called T3011, given as an injection, alone and with another drug called pembrolizumab, to see if it helps people with advanced solid tumors like melanoma and head and neck cancer.

  Recruiting at 8 sites Phase 1/2 ImmVira Pharma Co. Ltd · Gilbert, Arizona and 8 other locations · NCT04370587

• Combining Anti-PD-1 Therapy with Metformin and Rosiglitazone for Cancer Treatment

  This study is testing if combining a cancer treatment called anti-PD-1 therapy with two diabetes medications, Metformin and Rosiglitazone, can help people with advanced solid tumors fight their cancer better.

  Recruiting Phase 2 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT04114136

• Testing a new bispecific antibody for advanced solid tumors

  This study is testing a new treatment called MCLA-158 to see if it can help people with advanced solid tumors, especially those with metastatic colorectal cancer, when other options have run out.

  Recruiting at 45 sites Phase 1/2 Genmab · La Jolla, California and 53 other locations · NCT03526835

NIH-funded research (newest 40 of 53)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Lymph node metastasis and immune tolerance in head and neck cancer

  A study in people with head and neck cancer looks at how cancer spread to lymph nodes may shape the immune system and help tumors grow.

  NIH research Stanford University · Stanford, United States · NIH-11614785

• Restoring responses to immunotherapy in metastatic lymph nodes in head and neck cancer

  A clinical research project aims to improve how immunotherapy works when cancer has spread to lymph nodes in head and neck cancer patients.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11510384

• Data-driven classification of aggressive tissue traits to predict cancer outcomes in HPV-negative head and neck cancer

  A clinician-science grant uses data science and AI to identify tissue patterns in HPV-negative head and neck cancer that may predict how long patients stay cancer-free.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11505841

• HNSCC, iron addiction, and potential iron-targeted therapies

  This grant explores how head and neck cancer cells become dependent on iron and whether targeting iron pathways could lead to new treatments for patients with recurrent or metastatic disease.

  NIH research Virginia Commonwealth University · Richmond, United States · NIH-11441057

• Targeting SREBP2 to boost radiation therapy in HPV-negative head and neck cancer

  This grant aims to see if blocking SREBP2 can make radiation therapy work better for people with HPV-negative Head and Neck Squamous Cell Carcinoma.

  NIH research Indiana University Indianapolis · Indianapolis, United States · NIH-11427724

• Axelopran added to pembrolizumab for frontline recurrent/metastatic head and neck cancer

  A new treatment approach combines axelopran with pembrolizumab for people with PD-L1 positive recurrent/metastatic head and neck cancer to see if it improves response.

  NIH research Glycyx Mor, INC. · San Francisco, United States · NIH-11418514

• Understanding why some head and neck cancers stop responding to cisplatin and spread

  This project explores why certain head and neck cancers stop responding to cisplatin and how nerve signals inside tumors may drive metastasis, with goals that could lead to new ways to overcome drug resistance.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11416341

• Biomarkers for who will respond to immunotherapy in head and neck cancer

  A team at the University of Pittsburgh is studying biomarkers to predict which people with head and neck cancer will respond to immunotherapies that target PD-1 and LAG-3.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11404948

• Hypoxia and metabolism as targets to improve immunotherapy in head and neck cancer

  This grant tests new combinations of metabolic drugs with immunotherapy to help people with head and neck cancer respond better to treatment.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11404946

• Optimizing immunoradiotherapy for head and neck cancer

  Aims to improve immunotherapy for head and neck cancer by studying how draining lymph nodes affect treatment with PD-1 inhibitors and targeted radiation.

  NIH research University of California, San Diego · La Jolla, United States · NIH-11394504

• Taming immune blockers to improve radiation response in head and neck cancer

  This grant studies how immune cells called Tregs might keep radiation from working as well in head and neck cancer, and tests strategies to activate anti-cancer immunity to improve patient outcomes.

  NIH research Washington University · Saint Louis, United States · NIH-11384823

• Targeting the innate immune response in head and neck cancer

  This grant explores how to boost the body’s own immune defenses to treat head and neck squamous cell carcinoma (HNSCC) and help patients who may not respond to current immunotherapies.

  NIH research University of California, San Diego · La Jolla, United States · NIH-11382001

• Sex hormones and immune responses in head and neck cancer

  This grant studies how estrogen signaling and sex differences influence immune therapy responses in head and neck cancer to help tailor treatments for patients.

  NIH research Washington University · Saint Louis, United States · NIH-11370341

• Enhancing Dendritic Cell Movement to Lymph Nodes to Improve Immunotherapy in HPV-negative Head and Neck Cancer

  This grant aims to help people with HPV-negative head and neck cancer respond better to immunotherapy by guiding immune cells to the right lymph nodes.

  NIH research University of California, San Diego · La Jolla, United States · NIH-11370028

• Combination of PTPN2 inhibitor and STING agonist to boost immune response in head and neck cancer

  This grant tests a new combination treatment to help the immune system fight head and neck cancer in patients.

  NIH research Broad Institute, INC. · Cambridge, United States · NIH-11347426

• Targeting FOSL1 super-enhancers to overcome cisplatin resistance in head and neck cancer

  A patient-facing program aims to understand and disrupt the drivers of cisplatin resistance in head and neck cancer by focusing on cancer stem cells and the FOSL1 super-enhancer network.

  NIH research Virginia Commonwealth University · Richmond, United States · NIH-11333880

• Role of HPV Integration Structures in Head and Neck Cancer Diversity

  Researchers are studying how HPV-related genetic changes affect head and neck cancers to improve risk prediction and treatment choices for patients.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11323195

• How HPV-targeting immune cells affect immunotherapy responses in HPV-positive head and neck cancer

  This project looks at whether specific HPV-targeting T cells help people with HPV-positive head and neck cancer respond better to immune checkpoint drugs.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11306668

• Targeting LAG3 to improve pre-surgery immunotherapy in head and neck cancer

  This grant tests a combination immunotherapy before surgery to help people with head and neck cancer respond better to treatment.

  NIH research Yale University · New Haven, United States · NIH-11265320

• PLK1 blocker plus HER-targeted therapy to tackle resistance in head and neck cancer

  A study at Yale is exploring a new combination treatment to overcome resistance to EGFR-targeted therapy in head and neck cancer, using a PLK1 inhibitor with a pan-HER blocker.

  NIH research Yale University · New Haven, United States · NIH-11265318

• How estrogen affects immune responses in head and neck cancer

  This study is looking at how estrogen affects the immune system's response to treatment in patients with head and neck cancer, especially focusing on why premenopausal women seem to do better with immunotherapy, with the goal of finding new ways to improve treatment for everyone.

  NIH research Washington University · Saint Louis, United States · NIH-11250398

• Cyclin D1's role in head and neck cancer

  This work looks at how the protein cyclin D1 drives head and neck cancers to find new treatment targets for patients with cyclin D1-related tumors.

  NIH research Case Western Reserve University · Cleveland, United States · NIH-11248816

• Targeting an immune-cell protein (PI3Kgamma) to help head and neck cancer

  This research looks at whether blocking a protein called PI3Kgamma in certain immune cells can help people with head and neck squamous cell carcinoma respond better to treatment.

  NIH research University of California, San Diego · La Jolla, United States · NIH-11232346

• Using radiation and a combination of therapies to treat recurrent head and neck cancer.

  This study is looking at a new way to help people with recurring head and neck cancer by using a combination of radiation therapy and two special treatments that boost the immune system, hoping to make the cancer treatment more effective and improve recovery.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11192442

• Markers that predict response to LAG3 and PD‑1 immunotherapy for head and neck cancer

  This project looks for tumor and blood markers to help predict which people with head and neck squamous cell carcinoma will respond to PD‑1 and LAG‑3 immunotherapies.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11192286

• Targeting low oxygen and abnormal metabolism to help immunotherapy work better in head and neck cancer

  This research tests whether changing tumor oxygen levels and metabolism can help immunotherapy work better for people with recurrent or metastatic head and neck cancer.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11192275

• How a cell stress pathway and nerve changes cause cisplatin resistance and spread in head and neck cancer

  Scientists are targeting the NRF2 stress pathway and tumor-associated nerve changes to try to overcome cisplatin resistance in people with head and neck cancer.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11182531

• Investigating how FOSL1 affects cancer stem cells in head and neck cancer treatment

  This study is looking at how a protein called FOSL1 affects head and neck cancer cells and their ability to resist the chemotherapy drug cisplatin, with the goal of finding better treatments for patients who struggle with this resistance.

  NIH research Virginia Commonwealth University · Richmond, United States · NIH-11181285

• Combining radiation with drugs that block TGF‑beta and PD‑L1 for recurrent head and neck cancer

  This tests whether adding two immune‑targeting drugs that block TGF‑beta and PD‑L1 to radiation helps people whose head and neck cancer has come back respond better.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11180120

• Blocking EphB4–ephrinB2 to lower immune suppression in head and neck cancer

  This project tests whether blocking the EphB4–ephrinB2 pathway can reduce immune-suppressing cells in people with head and neck cancer to help radiation and immunotherapy work better.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11180119

• Using immune cells to fight head and neck cancer

  Trying treatments that change immune cells around head and neck tumors to help people with head and neck squamous cell carcinoma respond better to therapy.

  NIH research University of California, San Diego · La Jolla, United States · NIH-11161162

• Understanding how HPV affects head and neck cancer

  This study is looking at how the human papillomavirus (HPV) affects a specific type of throat cancer, aiming to find better ways to spot patients who might struggle with treatment, so they can get the help they need.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11146483

• Better immune and targeted radiation treatment for head and neck cancer

  This research tests whether protecting nearby lymph nodes during focused radiation together with PD‑1 immunotherapy helps people with head and neck squamous cell carcinoma, especially HPV‑negative tumors.

  NIH research University of California, San Diego · La Jolla, United States · NIH-11144432

• Understanding how sex hormones affect head and neck cancer

  This work explores why head and neck cancer affects more men than women and how estrogen might help women respond better to treatments.

  NIH research Washington University · Saint Louis, United States · NIH-11136504

• Using data science to identify aggressive cancer types and predict survival in head and neck cancer without HPV.

  This study is looking at a type of throat and neck cancer that isn't caused by HPV, and it aims to use new data techniques to better understand how different tissue types affect survival, which could help doctors make more personalized treatment choices for patients.

  NIH research Rutgers Biomedical and Health Sciences · Newark, UNITED STATES · NIH-11114716

• Investigating how exosomes contribute to the progression of head and neck cancer

  This study is looking at tiny particles released by cancer cells in head and neck cancer to see how they help the cancer grow and spread, with the hope that the findings could lead to better treatments or ways to diagnose the disease.

  NIH research Vanderbilt University · Nashville, UNITED STATES · NIH-11075132

• Understanding how certain proteins affect cancer treatment

  This study is looking at certain proteins that are important in how cancer grows and responds to treatment, with the goal of finding better ways to target these proteins in cancer therapies to help patients.

  NIH research Washington University · Saint Louis, United States · NIH-11071252

• Investigating how to prevent regional recurrence of head and neck cancer

  This study is looking at ways to stop head and neck cancer from coming back in the lymph nodes after treatment by boosting certain immune cells, which could help improve how the body fights the cancer and lead to better results for patients.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11067411

• Understanding how HPV-specific T cells affect treatment responses in head and neck cancer

  This study is looking at how certain immune cells that fight HPV might affect how well treatments work for people with HPV-related head and neck cancer, hoping to find ways to help more patients respond better to their treatment.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11056170

• Using IL-1 to enhance treatment for advanced head and neck cancer

  This study is looking at whether adding a special immune booster called interleukin-1 to regular treatments can help people with advanced head and neck cancer feel better and fight the disease more effectively.

  NIH research Iowa City VA Medical Center · Iowa City, United States · NIH-11050512

Related topics

Quick answers

How many HNSCC clinical trials are recruiting right now?

40, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 20 countries. The most sites are in United States (24 trials), China (9 trials), Germany (4 trials), Australia (4 trials), France (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 17, Phase 1/2: 8, Phase 2: 5, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →